Loomis, Sayles & Company
AERI

Loomis, Sayles & Company’s Aerie Pharmaceuticals AERI Stock Holding History

Loomis, Sayles & Company’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,872,070
Closed -$30M – 945
2021
Q2 		$30M Sell
1,872,070
-38,030
-2% -$652K 0.04% 251
2021
Q1 		$34.1M Sell
1,910,100
-6,143
-0.3% -$106K 0.04% 210
2020
Q4 		$25.9M Sell
1,916,243
-10,948
-0.6% -$132K 0.03% 230
2020
Q3 		$22.7M Buy
1,927,191
+745,413
+63% +$9.08M 0.03% 210
2020
Q2 		$17.4M Buy
+1,181,778
New +$17.5M 0.03% 242
2018
Q4 		– Sell
-371,215
Closed -$22.8M – 965
2018
Q3 		$22.8M Buy
371,215
+67,871
+22% +$4.36M 0.04% 195
2018
Q2 		$20.5M Buy
303,344
+35,672
+13% +$2M 0.04% 241
2018
Q1 		$14.5M Sell
267,672
-9,058
-3% -$507K 0.03% 330
2017
Q4 		$16.5M Sell
276,730
-1,479
-0.5% -$89.7K 0.03% 322
2017
Q3 		$13.5M Buy
+278,209
New +$15.2M 0.03% 364

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

Loomis, Sayles & Company's AERI Position: Q3 2021 in Review

Loomis, Sayles & Company sold out of Aerie Pharmaceuticals (AERI) in Q3 2021, closing a stake of 1,872,070 shares — an estimated $30M sold.

Loomis, Sayles & Company first reported a position in AERI in Q3 2017 and held it in 10 quarters. The position peaked at $34.1M in Q1 2021. 137 funds tracked by Wall St. Rank hold AERI as of Q3 2021.

  • Loomis, Sayles & Company reported no remaining Aerie Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 1,872,070 Aerie Pharmaceuticals shares in Q3 2021, an estimated $30M.
  • Loomis, Sayles & Company first reported a position in Aerie Pharmaceuticals in Q3 2017 and held it in 10 quarters.
  • Loomis, Sayles & Company's Aerie Pharmaceuticals position peaked at $34.1M in Q1 2021.
  • 137 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2021.

Based on Loomis, Sayles & Company's 13F filing for Q3 2021, filed 12 Nov 2021.